Vizz (Aceclidine)

Description

VIZZ (aceclidine ophthalmic solution) 1.44% is the first and only FDA-approved aceclidine-based eye drop designed to treat age-related blurry near vision (presbyopia) in adults. Administered once daily, it works within 30 minutes and delivers near-vision improvement that lasts up to 10 hours.

Aceclidine acts as a predominantly pupil-selective miotic, constricting the iris sphincter muscle to create a “pinhole effect” that extends depth of focus. This improves near vision without causing a myopic shift and with minimal stimulation of the ciliary muscle.

Clinical trials (the CLARITY studies) demonstrated robust efficacy, with significant near-vision improvements as early as 30 minutes post-dose and sustained results for up to 10 hours, alongside a favorable safety profile.

Directions

• Instill one drop in each eye once daily. Wait two minutes, then instill a second drop in each eye from the same single-dose vial.
• Contact Lenses: Remove lenses before applying; they may be reinserted 10 minutes after use.
• Multiple Ophthalmic Products: If using other eye drops, administer them at least 5 minutes apart.
• Handling: Do not touch the vial tip to the eye or any surface to avoid contamination or injury. Discard the single-dose vial immediately after use.

Ingredients

• Active: Aceclidine hydrochloride 1.75% (equivalent to aceclidine 1.44%) – approximately 17.82 mg per mL.
• Inactive: Polysorbate 80, mannitol, hypromellose, edetate disodium dihydrate, sodium citrate dihydrate, water for injection. May contain hydrochloric acid or sodium hydroxide to adjust pH to 4.5–5.5.
• Formulation: Sterile, clear to opalescent, colorless to slightly yellow, preservative-free ophthalmic solution in single-dose vials.

Interactions

• Allow a 5-minute interval between VIZZ and any other topical ophthalmic medications.
• Remove contact lenses before applying. Lenses may be reinserted 10 minutes after instillation.

Cautions

• Blurred or dim vision may occur temporarily. Avoid driving or operating heavy machinery until vision clears.
• Retinal tear or detachment has been reported with other miotic agents in predisposed patients. A retinal examination is recommended before starting treatment. Seek immediate care if you notice flashes of light, floaters, or sudden vision loss.
• Iritis: May worsen inflammation in patients with a history of iritis or synechiae.
• Hypersensitivity: Do not use if allergic to aceclidine or any component of the formulation.
• Contamination risk: Avoid contact of the vial tip with the eye or any surface. Discard the vial immediately after use.

Side Effects

In clinical trials, the most common adverse reactions (occurring in 5% or more of patients) included:

• Instillation site irritation (about 20%)
• Dim vision (about 16%)
• Headache (about 13%)
• Conjunctival hyperemia (about 8%)
• Ocular hyperemia (about 7%)

Most side effects were mild, temporary, and resolved without treatment.

Product Code : 15416